Literature DB >> 18852223

IgA antiphospholipid antibodies are an independent risk factor for thromboses.

Y M Shen1, R Lee, E Frenkel, R Sarode.   

Abstract

Antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin and anti-beta(2)-glycoprotein I antibodies, mostly IgG isotype) are strong risk factors for thrombosis. Because a paucity of information on IgA isotype exists in the literature, we retrospectively evaluated the thrombotic significance of IgA antiphospholipid antibodies. We included 472 patients with clinical information on thrombotic events and complete laboratory work-up for antiphospholipid antibodies syndrome. Odds ratios (OR) of various antiphospholipid antibodies for thrombosis were calculated by univariate and multivariate analyses. Lupus anticoagulant alone was detected in 57 (12%) patients, ELISA-based antibodies (IgG, IgM, IgA) against cardiolipin, phosphatidylserine or beta(2)-glycoprotein-I alone were detected in 131 (28%) patients, whereas 80 (17%) patients had both. Antibody isotype distribution was IgG 32%, IgM 60% and IgA 56%. Univariate analysis showed a statistically significant risk of thrombosis in patients with elevated titres of IgA of any ELISA-based antiphospholipid antibodies (OR 1.77). Stepwise logistic regression (multivariate) analysis identified elevated titres of any ELISA-based IgA antiphospholipid antibodies as an independent risk factor for thrombosis (OR 1.6) in the entire cohort, and in the subgroup of patients without concurrent presence of lupus anticoagulant (OR 1.8). IgA antiphospholipid antibodies appear to be a significant independent risk factor for thrombosis, thereby meriting evaluation in patients with unexpected thrombosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852223     DOI: 10.1177/0961203308093460

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  14 in total

1.  Differential assay reactivity of immunglobulin A anti-ß2 glycoprotein I antibodies: implications for the clinical interpretation of antiphospholipid antibody testing.

Authors:  David B Hood; Karin R Snyder; Tammy R Buckner; Beth L Hurley; Kelly R Pitts; Luis R Lopez
Journal:  Eur J Rheumatol       Date:  2015-08-21

Review 2.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

3.  IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus.

Authors:  Nadera J Sweiss; Ronghai Bo; Reena Kapadia; Deborah Manst; Farzan Mahmood; Tara Adhikari; Suncica Volkov; Maria Badaracco; Mary Smaron; Anthony Chang; Joseph Baron; Jerrold S Levine
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

4.  Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients.

Authors:  Francesco Boin; Stefano Franchini; Elizabeth Colantuoni; Antony Rosen; Fredrick M Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2009-08

5.  Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.

Authors:  Vijaya Murthy; Rohan Willis; Zurina Romay-Penabad; Patricia Ruiz-Limón; Laura A Martínez-Martínez; Shraddha Jatwani; Praveen Jajoria; Alan Seif; Graciela S Alarcón; Elizabeth Papalardo; Jigna Liu; Luis M Vilá; Gerald McGwin; Terry A McNearney; Rashmi Maganti; Prashanth Sunkureddi; Trisha Parekh; Michael Tarantino; Ehtisham Akhter; Hong Fang; Emilio B Gonzalez; Walter R Binder; Gary L Norman; Zakera Shums; Marius Teodorescu; John D Reveille; Michelle Petri; Silvia S Pierangeli
Journal:  Arthritis Rheum       Date:  2013-12

6.  Prevalence of anti- beta2GPI antibodies and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome.

Authors:  Sabiha Anis; Ejaz Ahmed; Rana Muzaffar
Journal:  J Nephropathol       Date:  2013-07-01

Review 7.  Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies.

Authors:  Laura Andreoli; Micaela Fredi; Cecilia Nalli; Silvia Piantoni; Rossella Reggia; Francesca Dall'Ara; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

8.  Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual.

Authors:  M Frodlund; A Vikerfors; G Grosso; T Skogh; J Wetterö; K Elvin; I Gunnarsson; A Kastbom; Ö Dahlström; J Rönnelid; E Svenungsson; C Sjöwall
Journal:  Clin Exp Immunol       Date:  2018-09-12       Impact factor: 4.330

9.  Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus.

Authors:  Selcan Demir; Jessica Li; Laurence S Magder; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

10.  Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Authors:  George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas
Journal:  Ann Rheum Dis       Date:  2012-07-31       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.